Nanomedicines for kidney diseases

Ryan M Williams; Edgar A Jaimes; Daniel A Heller

doi:10.1016/j.kint.2016.03.041

Nanomedicines for kidney diseases

Kidney Int. 2016 Oct;90(4):740-5. doi: 10.1016/j.kint.2016.03.041. Epub 2016 Jun 9.

Authors

Ryan M Williams¹, Edgar A Jaimes², Daniel A Heller³

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA. Electronic address: jaimese@mskcc.org.
³ Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA. Electronic address: hellerd@mskcc.org.

Abstract

Nanomedicines have been the subject of great interest for the treatment, diagnosis, and research of disease; however, few specifically address kidney disorders. Nanotechnology can confer significant benefits to medicine, such as the targeted delivery of drugs to specific tissues. Nanomedicines in the clinic have increased drug solubility, reduced off-target side effects, and provided novel diagnostic tools. There is an increasing cohort of nanomaterials that may have implications for kidney disease. Here, we review nanomaterial properties that are potentially applicable to kidney research and therapy, and we highlight clinical areas of need that may benefit from kidney nanomedicines.

Keywords: diagnostics; drug development; imaging; nanoparticles; theranostics; therapeutics.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Drug Delivery Systems / methods*
Humans
Kidney / drug effects*
Kidney Diseases / therapy*
Nanomedicine / methods*
Nanoparticles / chemistry
Nanoparticles / therapeutic use*
Renal Elimination

Abstract

Publication types

MeSH terms

Grants and funding